During the past decade, Northwest Heart Clinical Research, LLC conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 13 clinical trials were completed, i.e. on average, 72.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 10 clinical trials were completed. i.e. 111.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Northwest Heart Clinical Research, LLC" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Amgen" with 3 trials sponsored, "NewAmsterdam Pharma" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Northwest Heart Clinical Research, LLC" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Janssen Biotech, Inc." with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Northwest Heart Clinical Research, LLC" are "Cardiovascular Disease" (4 trials), "Heart Failure" (4 trials), "Atherosclerotic Cardiovascular Disease" (3 trials), "Obesity" (2 trials) and "Stroke" (2 trials). Many other conditions were trialed in "Northwest Heart Clinical Research, LLC" in a lesser frequency.

Most popular intervention types in "Northwest Heart Clinical Research, LLC" are "Drug" (19 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Empagliflozin" (4 trials), "Obicetrapib" (2 trials), "Tirzepatide" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Northwest Heart Clinical Research, LLC" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Northwest Heart Clinical Research, LLC". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Northwest Heart Clinical Research, LLC, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Northwest Heart Clinical Research, LLC, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".